SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli (Losartan Potassium)

Company launches multi-channel promotional campaign to drive market adoption

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli as the first FDA-approved ready-to-use oral suspension

SCIENTURE HOLDINGS, a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, announced the start of commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension, 10 mg/mL, marking an important milestone in the Company’s growth as it begins to bring this differentiated product to market.

Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. According to IQVIA data (MAT June 2025), the U.S. losartan market totals approximately $256 million in annual sales, with more than 71 million prescriptions written each year, presenting a significant commercial opportunity for Scienture and its distribution partners.

Marketing Technology News: MarTech Interview with Liat Barer, Chief Product Officer @ Odeeo

As part of its commercial campaign, Scienture is executing targeted outreach for Arbli to healthcare professionals (HCPs) and has finalized PBM-Led GPO agreements for expanded commercial coverage and formulary access. In addition, Scienture has also formalized multiple commercial group purchasing organization (GPO) agreements, expanding Arbli’s market access to over 2,500 healthcare institutions nationwide. This includes hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, collectively representing potential penetration into an estimated 20% of the U.S. institutional market. The agreements also establish a broad footprint across long-term care and outpatient facilities, strengthening the company’s commercial reach.

“The start of commercial sales for Arbli represents a major achievement for Scienture as we transition from development to execution,” commented Narasimhan Mani, President and co-CEO of Scienture. “As promotional efforts expand and demand builds across retail, institutional and long-term care markets, we see significant potential for sustained adoption and value creation.”

“Arbli embodies our mission to deliver patient-focused pharmaceutical solutions that improve access and convenience,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We are encouraged by the early response from healthcare institutions and remain committed to expanding education, awareness, and availability of this first-of-its-kind treatment option.”

Marketing Technology News: What Marketers Need to Know About the European Accessibility Act

Follow PressReleaseDistribution on Instagram